Aktis Oncology has initiated a Phase 1b clinical trial for AKY-2519, a targeted radioconjugate aimed at treating metastatic castration-resistant prostate cancer (mCRPC) expressing B7-H3. This trial includes patients both new to and experienced with PLUVICTO® therapy, with preliminary results expected in 2027. The company also plans a second Phase 1b basket trial for other B7-H3 expressing solid tumors like lung and colorectal cancers later in 2026, aiming to broaden treatment options and gather robust clinical data. This development addresses unmet needs in prostate cancer treatment, especially for patients ineligible or unresponsive to current PSMA-targeted therapies.
Uber Technologies Inc. has made a full takeover offer for Delivery Hero at €33 per share, slightly below Delivery Hero's recent closing price. Prior to the offer, Uber increased its stake in Delivery Hero from about 7% to 19.5%, becoming the largest ...
Clearpool has originated $930 million in institutional credit loans since its 2021 launch, focusing on bringing real-world borrowing onto blockchain with a compliance-first approach. The protocol targets institutional borrowers like hedge funds and f...
StablR's euro (EURR) and dollar (USDR) stablecoins lost their pegs following a security breach where an attacker compromised a private key controlling minting permissions. The attacker minted 12.85 million tokens and converted them through decentrali...
Bank of America has reallocated its cryptocurrency portfolio in Q1 2026 by increasing its investment in Bitcoin, particularly through BlackRock's iShares Bitcoin Trust, which now makes up about 70% of its crypto holdings. Meanwhile, the bank has redu...
In the past 48 hours, nearly $954 million in crypto long positions were liquidated amid market volatility, yet ZCash (ZEC) maintained a strong bullish trend. The token broke out of a short-term range, supported by steady buying pressure and capital i...
